Hosking Partners LLP Lowers Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Hosking Partners LLP trimmed its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,491 shares of the medical research company’s stock after selling 501 shares during the period. Hosking Partners LLP owned approximately 0.19% of Bio-Rad Laboratories worth $13,272,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BIO. LPL Financial LLC grew its position in Bio-Rad Laboratories by 34.3% in the 4th quarter. LPL Financial LLC now owns 5,195 shares of the medical research company’s stock valued at $1,707,000 after buying an additional 1,326 shares during the last quarter. O Shaughnessy Asset Management LLC purchased a new position in Bio-Rad Laboratories in the 4th quarter valued at $245,000. Envestnet Asset Management Inc. grew its position in Bio-Rad Laboratories by 6.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 105,027 shares of the medical research company’s stock valued at $34,502,000 after buying an additional 6,287 shares during the last quarter. Shelton Capital Management purchased a new position in Bio-Rad Laboratories in the 4th quarter valued at $237,000. Finally, Raymond James Financial Inc. purchased a new position in Bio-Rad Laboratories in the 4th quarter valued at $5,119,000. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BIO. Wall Street Zen upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Citigroup decreased their target price on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company boosted their target price on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. UBS Group decreased their target price on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating on the stock in a research report on Friday, May 2nd. Finally, Royal Bank Of Canada boosted their target price on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $333.50.

Bio-Rad Laboratories Trading Down 0.3%

NYSE:BIO opened at $264.45 on Friday. The company has a market capitalization of $7.16 billion, a PE ratio of 22.54 and a beta of 0.90. The company has a quick ratio of 3.67, a current ratio of 5.12 and a debt-to-equity ratio of 0.17. Bio-Rad Laboratories, Inc. has a 52-week low of $211.43 and a 52-week high of $387.99. The stock has a fifty day simple moving average of $245.28 and a 200-day simple moving average of $258.31.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.68. The business had revenue of $651.60 million during the quarter, compared to the consensus estimate of $614.82 million. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%. The business’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.11 EPS. On average, equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.